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Abstract
Background: The glycopeptide antibiotic vancomycin com-
plexes DAla-DAla termini of bacterial cell walls and peptidoglycan
precursors and interferes with enzymes involved in murein
biosynthesis. Semisynthetic vancomycins incorporating hydropho-
bic sugar substituents exhibit efficacy against DAla-DLac-contain-
ing vancomycin-resistant enterococci, albeit by an undetermined
mechanism. Contrasting models that invoke either cooperative
dimerization and membrane anchoring or direct inhibition of
bacterial transglycosylases have been proposed to explain the
bioactivity of these glycopeptides.
Results : Affinity chromatography has revealed direct interac-
tions between a semisynthetic hydrophobic vancomycin (DCB-
PV), and select Escherichia coli membrane proteins, including at
least six enzymes involved in peptidoglycan assembly. The N(4)-
vancosamine substituent is critical for protein binding. DCB-PV
inhibits transglycosylation in permeabilized E. coli, consistent with
the observed binding of the PBP-1B transglycosylase-transpepti-
dase.
Conclusions: Hydrophobic vancomycins interact directly with a
select subset of bacterial membrane proteins, suggesting the
existence of discrete protein targets. Transglycosylase inhibition
may play a role in the enhanced bioactivity of semisynthetic
glycopeptides. ß 2001 Elsevier Science Ltd. All rights reserved.
Keywords: A⁄nity chromatography; Glycopeptide; Peptidogly-
can; Transglycosylase; Vancomycin
1. Introduction
Vancomycin is the antibiotic of choice in the treatment
of methicillin-resistant Staphylococcus aureus (MRSA) in-
fections [1]. The glycopeptide forms high a⁄nity com-
plexes with terminal DAla-DAla dipeptides in nascent pep-
tidoglycan and peptidoglycan precursors (lipid II) [2],
which sterically interferes with the assembly of the bacte-
rial cell wall [3,4], resulting in osmotic lysis and cell death.
Three decades after its introduction, resistance to vanco-
mycin was reported in certain enterococci [5], caused by
the replacement of DAla-DAla moieties in the peptidogly-
can with DAla-DLac [6]. This modi¢cation results in a
1000-fold decrease in the a⁄nity of the glycopeptide for
the depsipeptide substrate [7], with a concomitant loss of
bioactivity. Vancomycin is the last line of defense in
the treatment of infections caused by multi-drug-resistant
bacteria, and the emergence of vancomycin-resistant en-
terococci (VRE) is viewed with trepidation, given the
possibility of resistance transfer to L-lactam-insensitive
staphylococci and streptococci [8,9].
Recent reports of N-alkylated hydrophobic glycopep-
tides that retain potency against vancomycin-resistant bac-
teria [10^12] o¡er promise in the development of novel
antimicrobials for clinical use against resistant strains.
The molecular logic that governs the bioactivity of these
semisynthetic glycopeptides (including biphenyl chloroere-
momycin [13] and chlorobiphenyl vancomycin (CBP-V)
[14]), however, remains a matter of debate. Williams and
co-workers have proposed that glycopeptide dimerization
and membrane anchoring by the lipophilic substituent act
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cooperatively [15] to create a chelate e¡ect [16] that in-
creases the a⁄nity for DAla-DLac in resistant bacteria
[17,18]. Alternatively, Kahne and co-workers have sug-
gested that certain hydrophobic glycopeptides exhibit a
second mode of action, independent of dipeptide/depsipep-
tide complexation [14,19]. In their studies, CBP-V and
other vancosamine-N(4)-substituted derivatives inhibited
the transglycosylase activity associated with glycan poly-
merization in ether-permeabilized Escherichia coli, whereas
vancomycin itself inhibited the subsequent transpeptida-
tion (cross-linking) step [14]. The substituted vancomycins
were proposed to interact directly with speci¢c bacterial
enzymes, a phenomenon that is distinct from the steric
interference a¡orded by vancomycin complexed to the
cell wall [3]. We have now utilized a⁄nity chromatography
to test this hypothesis, and have screened solubilized
E. coli membrane proteins for potential protein targets
using immobilized glycopeptide ligands.
2. Results
2.1. Construction of glycopeptide a⁄nity columns
Vancomycin was derivatized with a putrescine linker at
the C-terminus (putrescinyl vancomycin, PV, Fig. 1) to
facilitate immobilization on an acid-derivatized solid sup-
port for a⁄nity chromatography. The bioactivity of PV
against sensitive Gram-positive strains was not adversely
a¡ected by the presence of this linker (Table 1). The N(4)-
alkylated 3,4-dichlorobenzyloxybenzyl (DCB) derivative of
glycopeptide PV (DCB-PV, Fig. 1) was adopted as a pro-
totypic hydrophobic vancomycin for investigating poten-
tial interactions with speci¢c bacterial proteins. As sum-
marized in Table 1, this semisynthetic vancomycin, which
incorporates a hydrophobic aryl substituent at the N(4)
position of the vancosamine sugar (R2 in Fig. 1) exhibits
e⁄cacy against a broad range of Gram-positive bacteria,
including VRE (both teicoplanin-resistant VanA and tei-
coplanin-sensitive VanB strains), methicillin-sensitive
S. aureus, and MRSA (Table 1). The DCB-PV glycopep-
tide was immobilized for a⁄nity chromatography by cou-
pling the C-terminal linker to N-hydroxysuccinimide
(NHS)-activated Sepharose 4B. A control a⁄nity column
was similarly constructed using glycopeptide PV, which
has an unsubstituted disaccharide core and is ine¡ective
against VRE (Table 1).
2.2. A⁄nity chromatography of E. coli membrane proteins
The search for potential protein targets of hydrophobic
vancomycins in E. coli focused on membrane prepara-
tions, since glycopeptide antibiotics do not penetrate the
Fig. 1. Chemical structure of vancomycin and its derivatives used in this
study. The putrescine linker was appended to the carboxy-terminus of
glycopeptides DCB-PV and PV to facilitate immobilization on a solid
support. The DCB moiety was similarly immobilized for a⁄nity chro-
matography using the putrescinyl derivative DCBH. The corresponding
N-acetylated derivative (DCBA) mimics this N(4) substituent.
Table 1
Minimum inhibitory concentrations (MICs, Wg/ml) of the various glycopeptides and side chain analogs used in this study
Compound VSE VanA VanB MSSA MRSA
Vancomycin 2 2048 2048 1 1
Teicoplanin 0.5 s 1024 9 0.5 0.25 1
DCB-PV 9 0.03 2 2 9 0.03 0.5
PV 0.5 s 64 s 64 1 1
DCBA 32 32 64 64 64
The compounds were tested against vancomycin-sensitive enterococci (VSE, E. faecium strain RLA1), vancomycin-resistant enterococci of the VanA and
VanB subtypes (E. faecium strain CL5053 and E. faecalis strain CL4877, respectively), methicillin-sensitive S. aureus (MSSA, strain MB2985), and meth-
icillin-resistant S. aureus (MRSA, strain COL).
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outer cell wall [20]. The use of a hydrophobic vancomycin
as ligand in a⁄nity chromatography, however, raised the
possibility of non-speci¢c glycopeptide^protein interac-
tions. In addition, the limited quantities of glycopeptide
available necessitated modi¢cations to the elution proto-
cols typically employed in such experiments. Both issues
were addressed in the design of the chromatography pro-
tocols. E. coli K12 membranes prepared by di¡erential
centrifugation were solubilized with a non-ionic detergent
(1% (w/v) Triton X-100) and high salt (1 M NaCl) in
bu¡er A (20 mM sodium phosphate bu¡er, pH 7.0). In
a typical chromatography experiment, solubilized mem-
brane proteins (500 Wl, containing 3^8 mg of total protein,
and clari¢ed by ultracentrifugation) were loaded on the
DCB-PV a⁄nity column (7^12 Wmol capacity, 1 ml bed
volume). Since hydrophobic interactions increase with
ionic strength and are dependent on the chemical nature
of the salt present in the mobile phase, these parameters
were optimized to minimize potentially indiscriminate pro-
tein binding by the glycopeptide ligands.
The addition of salts increases the surface tension of
water and favors the structural rearrangements of solvent
molecules surrounding interacting hydrophobic groups,
which is thought to provide the driving force for hydro-
phobic interactions (the ‘salting out’ e¡ect) [21]. Cations
and anions are ranked in the Hofmeister series (for a re-
view, see [22]), as per their molal surface tension increment
(c) in water. Salts with high c values are commonly used
to increase protein adsorption in hydrophobic interaction
chromatography. For example, ammonium sulfate
(c= 2.16) produces a molal salting-out constant for hemo-
globin of 3.86 m31 compared to only 0.62 m31 with so-
dium chloride (c= 1.64) [22,23]. We therefore speci¢cally
avoided salts such as ammonium sulfate, and instead, ad-
justed the ionic strength of the mobile phase with NaCl to
minimize the potential for non-speci¢c adsorption of hy-
drophobic proteins to the glycopeptide ligands.
Representative fractions (1 ml each) that were collected
from the DCB-PV a⁄nity column were analyzed by so-
dium dodecyl sulfate^polyacrylamide gel electrophoresis
(SDS^PAGE) on a 10% polyacrylamide gel, which was
silver-stained to maximize the sensitivity of protein detec-
tion (Fig. 2a). An extensive wash of the charged DCB-PV
a⁄nity column with 20 column volumes of bu¡er A con-
taining 400 mM NaCl, 0.05% Triton X-100 was most ef-
fective in eluting non-speci¢cally bound proteins. Due to
the moderate ionic strength of the mobile phase, any salt-
ing-out e¡ect was minimal, and non-speci¢c electrostatic
(polar) glycopeptide^protein interactions were also sup-
pressed. As shown in Fig. 2a, proteins bound with low
a⁄nity were rapidly stripped from the DCB-PV a⁄nity
column during the wash (column volumes 1^5). The ab-
sence of protein in fractions corresponding to the latter
half of this ‘high stringency’ wash (column volumes 10^
20) con¢rmed the elimination of most low a⁄nity glyco-
peptide^protein interactions under these optimal condi-
tions. In contrast, the utilization of a wash bu¡er with
high ionic strength (1 M NaCl) resulted in the extensive
salting-out of hydrophobic proteins, which continuously
leached from the column, indicative of low a⁄nity inter-
Fig. 2. A⁄nity chromatography of semisynthetic vancomycins and the
DCBH ligand. (a) SDS^PAGE (10% polyacrylamide, silver-stained) of
select fractions (identi¢ed by column volumes) collected during the pas-
sage of solubilized E. coli membrane proteins through the DCB-PV af-
¢nity column. (b) A similar analysis of representative fractions from the
corresponding PV a⁄nity column. (c) SDS^PAGE analysis of fractions
from the DCBH a⁄nity column, which mimics the N(4) substituent of
DCB-PV.
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actions (data not shown). The elution of these proteins
was not facilitated by the addition of free glycopeptide,
consistent with non-speci¢c protein binding by the im-
mobilized DCB-PV ligand under these high salt condi-
tions.
A small subset of E. coli membrane proteins (approx-
imately 3^4% of the total protein mass loaded on the
column) were retained by the DCB-PV a⁄nity column
after the high stringency (400 mM NaCl) wash, which
selects for high a⁄nity glycopeptide^protein interactions.
Elution of these proteins by the addition of free ligand to
the mobile phase (a standard protocol in a⁄nity chroma-
tography) was precluded by the limited quantities of gly-
copeptide available. Attempts to perturb the glycopeptide^
protein interactions by washing the column with a mobile
phase of drastically reduced ionic strength (bu¡er A, 1%
Triton X-100) led to ine⁄cient release of bound proteins
(V40%). Instead, the column was incubated overnight
with a low concentration of DCB-PV (100 WM) in the
low ionic strength bu¡er. Released proteins were subse-
quently £ushed from the column with the same bu¡er,
except that no glycopeptide was present in the mobile
phase. This scheme, necessitated by the limited quantities
of free glycopeptide available for competitive elution, in-
evitably resulted in a broad elution pro¢le (V12 column
volumes, Fig. 2a). Nevertheless, protein recoveries using
this strategy were quite acceptable (s 90%).
To determine the contributions of the N(4) aromatic
substituent in DCB-PV to protein binding, the a⁄nity
chromatography experiment was repeated with immobi-
lized PV, which contains an unsubstituted disaccharide
core. No proteins eluted from this a⁄nity column after
incubation with a 100 WM solution of PV (Fig. 2b), indi-
cating that the unalkylated glycopeptide does not signi¢-
cantly interact with proteins. In a second control experi-
ment, no E. coli membrane proteins were retained by an
ethanolamine-derivatized Sepharose 4B column under
identical chromatography conditions (data not shown),
con¢rming that the column matrix itself does not signi¢-
cantly bind any protein.
2.3. DCB-PV interacts with penicillin binding proteins
involved in peptidoglycan biosynthesis
Aliquots of the eluate (200 Wl) from both glycopeptide
a⁄nity columns were treated with 50 WM Bocillin-FL1, a
£uorescent L-lactam that covalently labels penicillin bind-
ing proteins (PBPs) [24]. After a brief incubation (30 min,
25‡C), the samples were concentrated by acetone precip-
itation and resolved by SDS^PAGE on a 10% polyacryl-
amide gel. The gel was scanned with a £uorimager
(Vex = 480 nm, Vem = 530 nm) to reveal any PBPs that
may be present. As shown in Fig. 3, several E. coli PBPs
(PBPs 1B, 2, 3, 5, and 6, each identi¢ed by molecular
mass, see below) were speci¢cally eluted from the DCB-
PV column. No PBPs were present in the elution fractions
from the PV column (data not shown), consistent with the
absence of any signi¢cant protein binding by this glyco-
peptide.
2.4. Mass spectrometric identi¢cation of membrane proteins
that bind DCB-PV
Proteins eluting from the DCB-PV a⁄nity column were
concentrated by acetone precipitation, resolved by SDS^
PAGE, and stained with Gelcode Blue1. Ten discrete
protein-containing bands (Fig. 4) were excised from the
gel and digested in situ with trypsin. The resulting proteo-
lytic fragments were extracted from the gel slices and sub-
jected to liquid chromatography-tandem mass spectrome-
try (MS/MS) analysis. The MS/MS spectra of tryptic
fragments were subjected in batch mode to SEQUEST
[25], a direct database correlation algorithm. Identi¢ed
proteins were validated by manual inspection of the se-
quence ions present in each spectrum. Several analyzed
bands were observed to contain more than one protein.
As summarized in Fig. 4, the lipophilic glycopeptide DCB-
PV interacts with at least 13 diverse membrane proteins,
including redox enzymes and components of transporter
complexes. Signi¢cantly, a majority of the identi¢ed pro-
teins play a role in peptidoglycan biosynthesis and turn-
over (highlighted in Fig. 4), although their relative abun-
Fig. 3. Comparison of PBPs eluted from the DCB-PV and DCBH a⁄n-
ity columns. The eluate from each a⁄nity column (column volume 22,
Fig. 2a,c) was treated with a £uorescent L-lactam (Bocillin-FL), resolved
by SDS^PAGE, and scanned with a £uorimager. Five PBPs that inter-
act with DCB-PV were identi¢ed by molecular mass, including a bifunc-
tional transpeptidase transglycosylase (PBP-1B), two transpeptidases
(PBPs 2,3), and two endopeptidases (PBPs 5,6). Of these proteins, PBPs
2 and 3 are not signi¢cantly retained by the DCBH a⁄nity column.
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dance in the eluate cannot be ascertained by the MS anal-
ysis. The detection of PBPs 1B, 2, 3, 5, and 6 by MS
con¢rmed the results of the earlier Bocillin-FL labeling
experiment. Unfortunately, the MS analysis of high mo-
lecular weight bands (v100 kDa) was hindered by poor
signal-to-noise ratios, probably due to the hydrophobicity
of the corresponding membrane proteins. No useful MS
data could be collected for band 1, and PBP-1B was only
intermittently detected by MS in band 2, even though the
Bocillin labeling was consistently reproducible.
2.5. Protein binding by DCB-PV is mediated by the
vancosamine-N(4) aryl substituent
Since an unsubstituted vancomycin (PV) does not sig-
ni¢cantly interact with bacterial membrane proteins, the
vancosamine-N(4) substituent of DCB-PV was immobi-
lized to evaluate its contribution to protein binding. The
DCB moiety was coupled to NHS-activated Sepharose via
a putrescine linker (ligand DCBH, Fig. 1), which mimics
the N-alkyl connectivity of this side chain to the glycopep-
tide. A⁄nity chromatography was performed as described
for the glycopeptide ligands, and bound protein was dis-
placed after preincubating the column with a 100 WM so-
lution of DCBA (the N-acetylated derivative of DCBH,
Fig. 1). Since the chromatography protocols were opti-
mized to minimize non-speci¢c interactions, a protein elu-
tion pro¢le similar to that obtained with the DCB-PV
glycopeptide indicated that the immobilized DCB moiety
itself exhibits a high a⁄nity for a limited number of E. coli
membrane proteins (Fig. 2c). Bicyclic aryl moieties such as
DCB may be especially e¡ective in this regard, since phe-
nyl Sepharose (a prototypic hydrophobic interaction chro-
matography medium) did not bind any proteins under
these chromatography conditions (data not shown). These
data suggest that the N(4) substituent of DCB-PV may
function as a protein binding determinant. Signi¢cant dif-
ferences in protein binding were observed, however, be-
tween the DCB-PV and DCBH a⁄nity columns, especially
in the pattern of interacting PBPs. Bocillin-FL labeling
revealed that PBP-2 and PBP-3 were not signi¢cantly re-
tained by the DCBH column (Fig. 3), although the other
PBPs that interact with DCB-PV (PBPs 1B, 5, and 6) were
present.
2.6. DCB-PV inhibits transglycosylase activity in
permeabilized E. coli
The identi¢cation of at least six enzymes involved in
peptidoglycan synthesis as proteins that interact with
DCB-PV prompted us to investigate the e¡ects of this
glycopeptide on late stage peptidoglycan biosynthesis (re-
viewed in [26]) in a permeabilized-cell ‘site of inhibition
assay’ described previously [14]. Brie£y, radiolabeled
UDP-N-acetylglucosamine ([U-14C]UDP-GlcNAc) and
UDP-MurNAc-pentapeptide (bacterial cell wall precur-
sors, Fig. 5) were added to ether-permeabilized E. coli in
the presence of increasing concentrations of glycopeptide.
The extent of radioactivity incorporated into cytoplasmic
lipid intermediates (extractable into n-butanol, BuOH),
immature glycan (insoluble in dimethyl sulfoxide and re-
tained on a polyvinylidene £uoride (PVDF) membrane),
      
                   
                        
                   
                    
                  
                   
                   
                
                   
            
 
Fig. 4. Mass spectrometric identi¢cation of E. coli membrane proteins that interact with DCB-PV. Proteins eluting from the a⁄nity column were re-
solved by SDS^PAGE. Major protein-containing bands (numbered 1^10) were excised and digested in situ with trypsin. Proteins were identi¢ed on the
basis of tryptic fragments, which were analyzed by tandem electrospray mass spectrometry and SEQUEST database correlation. The NCBI accession
number for each identi¢ed protein is listed. Proteins highlighted in red are enzymes involved in cell wall biosynthesis and turnover.
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and mature (cross-linked) peptidoglycan (insoluble in hot
4% SDS) was measured to determine the step at which
peptidoglycan synthesis is inhibited. Since transglycosyla-
tion precedes transpeptidation in E. coli (Fig. 5), these
temporally distinct processes in late stage peptidoglycan
biosynthesis were delineated by repeating the assay in
the presence of penicillin G to inhibit the cross-linking
process and exclusively monitor the formation of imma-
ture (non-cross-linked) peptidoglycan. The permeabilized-
cell bioassay reveals only the earliest step in late stage
peptidoglycan biosynthesis that is inhibited by a particular
compound. Concomitant e¡ects on subsequent steps can-
not be ruled out by this assay.
The amount of hot SDS-insoluble [14C]GlcNAc-labeled
material formed in the ether-treated bacteria assay in
60 min at 30‡C was V700 pmol in the absence of inhib-
itors. Based on the extent of radiolabel incorporated, the
ratio of lipid I/II to nascent glycan to cross-linked pepti-
doglycan formed during this interval was approximately
1:2.4:5.7. The e¡ects of control compounds (ramoplanin,
moenomycin, cefoxitin, and vancomycin) that disrupt
speci¢c stages in peptidoglycan synthesis were consistent
with the identi¢cation of stated intermediates detected in
this assay (data not shown). Incorporation of radiolabel
into the BuOH-soluble fraction (lipid intermediates, Fig. 5)
was inhibited only by ramoplanin (a stage II inhibitor).
Both ramoplanin and moenomycin (a transglycosylase
inhibitor) inhibited incorporation of label into the penicil-
lin-resistant fraction (immature glycan, retained by
PVDF), whereas transpeptidase inhibitors (cefoxitin and
vancomycin) did not a¡ect this step. Predictably, all four
compounds inhibited incorporation of radiolabel into
cross-linked peptidoglycan (the hot SDS-insoluble frac-
tion).
As illustrated in Fig. 6a, DCB-PV inhibits the incorpo-
ration of radioactive label into nascent glycan (and sub-
sequently into mature peptidoglycan), with the concomi-
tant accumulation of radiolabeled lipid intermediates.
DCB-PV therefore interferes with early Stage III glycan
polymerization (IC50 = 4 WM), consistent with the speci¢c
inhibition of transglycosylases responsible for the incorpo-
ration of lipid II into existing glycan (Fig. 5). In contrast,
the unsubstituted glycopeptide PV inhibits the incorpora-
tion of radioactivity into mature (cross-linked) peptidogly-
can (Fig. 6b, IC50 = 62 WM), resulting in the accumulation
of immature glycan and lipid intermediates produced in
the preceding steps of cell wall assembly. These observa-
tions are consistent with PV interfering with the trans-
peptidases responsible for cross-linking of the nascent
peptidoglycan. The N(4) substituent of DCB-PV (3,4-di-
Fig. 5. Late stage peptidoglycan biosynthesis monitored using the ether-treated bacteria (ETB) bioassay. Radiolabeled [U-14C]UDP-GlcNAc and UDP-
MurNAc-pentapeptide (UDP-MurNAc-pp) were added to ether-permeabilized E. coli (ETB). Incorporation of the radiolabel into lipids (extracted into
n-butanol) and mature cross-linked peptidoglycan (insoluble in hot 4% SDS) was monitored in the presence of titrated compounds, to evaluate potential
inhibition of lipid intermediate formation in stage II, and transglycosylation/transpeptidation in stage III, respectively. The assay was repeated in the
presence of penicillin G (penG), which inhibits the cross-linking (transpeptidation) step, and allows for measurement of radiolabel incorporation into
nascent glycan (insoluble in dimethyl sulfoxide and retained by a PVDF ¢lter). Transglycosylase inhibitors are identi¢ed under these conditions, and dis-
tinguished from compounds that a¡ect only the subsequent transpeptidation step.
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chlorobenzyloxybenzyl derivative DCBA) also inhibited
peptidoglycan synthesis in ether-permeabilized E. coli,
but only at concentrations that were approximately 100-
fold higher than that of the parent DCB-PV glycopeptide
(Fig. 6c). Whereas DCB-PV inhibits transglycosylation,
DCBA itself inhibited the preceding step (formation of
Stage II lipid intermediates) in the bioassay.
2.7. A⁄nity chromatography with the glucosamine-acyl
substituents of teicoplanin
Teicoplanin, an amphiphilic glycopeptide antibiotic that
is related to vancomycin, is a complex of ¢ve major com-
ponents (TA2-1^5) that di¡er only in the structure of the
N-acyl substituent at the glucosamine sugar (Fig. 7a) [27].
In contrast to hydrophobic vancomycins such as DCB-PV,
teicoplanin exhibits poor e⁄cacy against DAla-DLac-con-
taining VRE (Table 1). Fatty acids analogous to the acyl
side chains of teicoplanin were immobilized and investi-
gated by a⁄nity chromatography to compare protein
binding by these aliphatic substituents with that by the
N(4)-DCB substituent of DCB-PV. A⁄nity columns
(V10 Wmol capacity each) were prepared by immobilizing
8-methylnonanoic acid (analogous to the TA2-2 acyl
chain), 10-methylundecanoic acid (one methylene unit lon-
ger than the TA2-5 side chain), and n-decanoic acid (cor-
responding to the TA2-3 substituent) on EAH Sepharose
4B as per the manufacturer’s instructions.
A⁄nity chromatography of solubilized E. coli mem-
branes revealed weak and varying degrees of protein bind-
ing by the aliphatic ligands (10-methylundecanoic
acidI8-methylnonanoic acid6 n-decanoic acid). Unlike
Fig. 6. Inhibition of late stage peptidoglycan biosynthesis by glycopeptides DCB-PV and PV, and by the N(4) substituent (DCBA) in ether-permeabi-
lized E. coli. Inhibition of a particular step in peptidoglycan biosynthesis precludes subsequent processes, and causes the accumulation of intermediates
in preceding steps (re£ected as ‘negative’ inhibition). In the absence of any inhibitor, the amount of radiolabel incorporated into each fraction after 60
min at 30‡C was as follows: lipid intermediates, 110 pmol (3penG), 136 pmol (+penG); cross-linked peptidoglycan, 704 pmol (3penG); immature gly-
can, 296 pmol (+penG). (a) Inhibition of transglycosylation by DCB-PV prevents the formation of nascent (and mature) peptidoglycan, and causes the
accumulation of lipid intermediates. (b) PV inhibits the subsequent transpeptidation step instead (formation of cross-linked mature glycan), albeit at 10-
fold higher concentrations, causing the accumulation of nascent glycan and lipid intermediates. (c) The hydrophobic N(4) substituent of DCB-PV
(DCBA) inhibits the formation of stage II lipid intermediates at high concentrations (s 100 WM), which also a¡ects subsequent transglycosylation and
transpeptidation.
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the high a⁄nity interactions observed with the DCB-PV
and DCBH a⁄nity columns, the continuous leaching of
multiple proteins from the acyl chain columns during the
high stringency wash step (Fig. 7b) suggested low a⁄nity
protein binding by the teicoplanin substituents. Protein
binding by the branched C9 and C10 ligands was too
weak to allow for the detection of interacting PBPs by
Bocillin-FL labeling. PBP-6 and PBP-1B were detected
in fractions eluting from the n-decanoic acid column
(data not shown), but these proteins were also present
in the wash fractions, indicative of non-speci¢c binding.
Incubation of these a⁄nity columns with free ligand (a
100 WM solution of the corresponding long chain carbox-
amide or methyl ester derivatives) did not signi¢cantly
facilitate the release of proteins, also suggestive of non-
speci¢c protein binding by the acyl substituents of teico-
planin.
3. Discussion
In this work, we have utilized a⁄nity chromatography
to determine whether direct glycopeptide^protein interac-
tions play a role in the bioactivity of semisynthetic hydro-
phobic vancomycins. In vitro, vancomycin inhibits either
transglycosylation or transpeptidation, depending on
whether it sequesters the DAla-DAla dipeptide in lipid II
intermediates or in the immature peptidoglycan, respec-
tively. Ether-permeabilized E. coli are moderately suscep-
tible to the antibiotic, which enables the mode of action of
                    
Fig. 7. A⁄nity chromatography with the acyl substituents of teicoplanin. (a) Chemical structures of glycopeptides TA2-1^5 that comprise the major
components of the teicoplanin complex. (b) SDS^PAGE of representative fractions (identi¢ed by column volume) collected during the passage of solubi-
lized E. coli membrane proteins through the n-decanoic acid a⁄nity column, which mimics the TA2-3 substituent.
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semisynthetic vancomycins to be studied in a Gram-neg-
ative strain where the major enzymes responsible for mur-
ein assembly are genetically and biochemically character-
ized.
The observation that DCB-PV interacts with a small
subset of E. coli membrane proteins is, to our knowledge,
the ¢rst such report of direct glycopeptide^protein inter-
actions. The high stringency wash step included in the
chromatography protocols suggests that the selectively re-
tained proteins are most likely bound with high a⁄nity to
the glycopeptide a⁄nity column. Displacement of a lim-
ited number of proteins (V13) from the column upon
incubation with free glycopeptide re£ects modest speci¢c-
ity in protein binding by DCB-PV. The signi¢cance of this
observation is highlighted by the complete absence of pro-
tein binding by PV, and by the weak non-speci¢c interac-
tions exhibited by the acyl substituents of teicoplanin;
both glycopeptides are ine¡ective against DAla-DLac-con-
taining VRE. The bioactivity of teicoplanin against these
strains is reported to be enhanced up to 500-fold in di-
substituted semisynthetic derivatives containing N-alkyl/
aryl substituents at the glucosamine sugar and at the ami-
no-terminus [28]. Whether the enhanced VRE activity of
these semisynthetic teicoplanins is due to e¡ective binding
of protein targets remains to be established, although in-
creased membrane anchoring of these glycopeptides at the
cell surface may also play a role.
Since a majority of the E. coli enzymes involved in pep-
tidoglycan assembly belong to the PBP superfamily (tar-
geted by the L-lactam antibiotics) [29], fractions eluting
from the a⁄nity columns were ¢rst treated with a £uores-
cent L-lactam that labels PBPs with a detection limit of
V20 ng. Five PBPs that interact with DCB-PV were iden-
ti¢ed by this method. The most abundant PBP in E. coli
(PBP-5, 791 molecules/cell [30]) was also the major protein
retained by the DCB-PV a⁄nity column. Five other pro-
teins were identi¢ed by MS analysis of their tryptic frag-
ments; these include the membrane-bound lytic murein
transglycosylase A (murein hydrolase A, MltA), which is
involved in cell wall remodeling [31], and components
of transporter complexes AcrA [32] and EIIB-Glc [33].
Two proteins corresponding to open reading frames
of unknown function were also identi¢ed in the MS anal-
ysis, as were the PBPs previously detected by covalent
labeling.
The identi¢cation of multiple PBPs that interact with
DCB-PV is noteworthy for several reasons. First, most
of these proteins are transpeptidases or endopeptidases
involved in cell wall assembly, and some of these enzymes
play an essential role in the morphological changes that
accompany bacterial cell growth (PBP-2) and division
(PBP-3) [34]. Second, the high molecular weight PBP-1B
protein detected in the DCB-PV eluate is a dual function
transglycosylase/transpeptidase that catalyzes up to 90%
of the peptidoglycan synthesis in E. coli [35,36]. This en-
zyme is therefore a putative target for the inhibition of
transglycosylase activity by DCB-PV that was measured
in the E. coli bioassay. Third, the elution of multiple PBPs
and a lytic transglycosylase may re£ect interactions of the
DCB-PV glycopeptide with multienzyme complexes that
are proposed to be involved in murein synthesis [37,38].
Such interactions could also contribute to the inhibition of
peptidoglycan biosynthesis. Consistent with these hypoth-
eses, DCB-PV e¡ectively inhibits transglycosylation in a
permeabilized-cell bioassay. The relevance of these obser-
vations (made in ether-treated E. coli) to the Gram-pos-
itive activity of substituted vancomycins is supported by a
recent report describing the inhibition of transglycosyla-
tion in VRE by chlorobiphenyldesleucyl vancomycin, a
glycopeptide similar to DCB-PV, but lacking the DAla-
DAla binding pocket [39].
Although our experiments suggest that DCB-PV, a hy-
drophobic vancomycin, interacts directly with bacterial
transglycosylases such as PBP-1B and MltA, the exact
mechanism of transglycosylase inhibition by this glycopep-
tide in permeabilized E. coli remains to be established.
Protein binding alone is not su⁄cient, since the N(4)-
DCB substituent (DCBA), which also binds PBP-1B, is
100-fold less potent in the bioassay, and inhibits an earlier
step (the formation of lipid intermediates). Potential non-
speci¢c hydrophobic e¡ects on transglycosylation due to
the N(4)-vancosamine substituent cannot explain the bio-
activity of DCB-PV, given the poor antimicrobial activity
of DCBA (MIC v32 Wg/ml, Table 1) and the high con-
centrations of this compound required to inhibit the for-
mation of lipid intermediates in the permeabilized-cell bio-
assay. Protein binding, while not su⁄cient, does appear to
be necessary for transglycosylase inhibition by DCB-PV,
since the unsubstituted PV glycopeptide inhibits transpep-
tidation instead, and only at 10-fold higher concentrations
(consistent with a prerequisite for stoichiometric binding
to DAla-DAla moieties). DCB-PV, if bound to a target
transglycosylase, should also be capable of sequestering
DAla-DAla/DLac dipeptide/depsipeptide moieties in proxi-
mal glycosyl donor and acceptor substrates, which could
further interfere with transglycosylation and glycan assem-
bly. Such bidentate chelation would be energetically fa-
vored since the complexation is e¡ectively intramolecular,
analogous to the chelate e¡ect invoked in alternate models
of glycopeptide VRE activity [15].
Our demonstration of interactions between an N(4)-van-
cosamine-substituted vancomycin derivative and key bac-
terial enzymes involved in peptidoglycan biosynthesis
lends support to the hypothesis of direct transglycosylase
inhibition, but does not rule out the possibility for addi-
tional modes of action. Depending on the structure and
connectivity of the hydrophobic substituent, the identity of
the glycopeptide core, and perhaps even the composition
of the bacterial cell wall, either or both of the proposed
mechanisms (direct enzyme inhibition versus cooperative
glycopeptide dimerization and membrane anchoring) may
govern the bioactivity of a particular substituted glycopep-
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tide. Indeed, Kerns et al. have recently reported that the
VRE activity of glucose-C(6)-substituted hydrophobic
vancomycins is critically dependent on the structural in-
tegrity of the DAla-DAla binding pocket, unlike that of the
corresponding N(4)-substituted derivatives [19]. Hence, the
challenge of establishing whether a particular mechanism
is more relevant to VRE activity lies ahead, as does an
investigation to determine the possible involvement of cy-
toplasmic protein targets or transglycosylases that may
have escaped detection in this study (e.g. the monofunc-
tional transglycosylases recently reported in E. coli [40,41]
and in other bacteria [42^44]). The presence of several
proteins of undocumented function in the eluate from
the DCB-PV a⁄nity column is of particular interest in
this regard, since these proteins may represent novel gly-
copeptide targets in E. coli. In conclusion, the implications
of direct protein interactions should clearly be considered
in future mechanistic studies of hydrophobic glycopeptide
derivatives.
4. Signi¢cance
In this work, we have used a⁄nity chromatography to
demonstrate that DCB-PV, a 3,4-dichlorobenzyloxybenzyl
vancomycin derivative incorporating the aromatic sub-
stituent at the N(4) position of the vancosamine sugar,
interacts directly with a small subset of membrane-associ-
ated E. coli proteins, the majority of which are involved in
cell wall biosynthesis and turnover. In contrast, the corre-
sponding N(4)-unsubstituted glycopeptide, PV, does not
signi¢cantly bind any particular protein. The retention of
known E. coli transglycosylases (PBP-1B, MltA) on a
DCB-PV a⁄nity column, together with the inhibition of
transglycosylase activity in ether-permeabilized bacteria by
this semisynthetic glycopeptide, is consistent with the hy-
pothesis that speci¢c glycopeptide^protein interactions
play a role in the bioactivity of N(4)-alkylated hydropho-
bic vancomycins. The N(4)-vancosamine substituent was
identi¢ed as a likely protein binding determinant, although
the glycopeptide moiety is also critical for bioactivity.
These studies provide the ¢rst evidence for direct glyco-
peptide^protein interactions in bacteria and lay the foun-
dation for investigating the role of protein binding in the
VRE activity of hydrophobic vancomycins.
5. Materials and methods
The semisyntheses of DCB-PV and PV will be reported else-
where [45]. E. coli wild type K12 strain MB4113A and all Gram-
positive bacterial strains were obtained from the Merck Culture
Collection. NHS-activated Sepharose 4B Hi-Trap columns and
EAH Sepharose 4B resin were obtained from Amersham Phar-
macia Biotech (Piscataway, NJ, USA). Bradford reagent and
SDS^PAGE molecular mass standards were from Bio-Rad Lab-
oratories (Hercules, CA, USA). Bocillin-FL1 was purchased
from Molecular Probes (Eugene, OR, USA). Gelcode Blue1
stain was obtained from Pierce (Rockford, IL, USA). 8-Methyl-
nonanoic acid, 10-methylundecanoic acid, and n-decanoic acid
were from Sigma (St. Louis, MO, USA). The permeabilized-cell
‘site of inhibition’ transglycosylase assay has been described in
detail elsewhere [14]. [U-14C]UDP-GlcNAc was obtained from
NEN Life Science Products (Boston, MA, USA) and UDP-
MurNAc-pentapeptide was prepared from vancomycin-treated
Bacillus megaterium MB410 based on the methods of Moore et
al. [46].
5.1. MIC determination
The MIC of each strain was determined by broth microdilution
according to NCCLS guidelines [47], except that brain^heart in-
fusion broth (Difco Laboratories, Detroit, MI, USA), which sup-
ports optimal growth of enterococci, was the test medium and the
inoculum was 5^10 times higher than the recommended 3^7U105
CFU/ml. Cloned strains maintained at 4‡C on brain^heart infu-
sion agar (Difco) slants and grown overnight in trypticase soy
broth (Becton Dickinson Microbiology Systems, Cockeysville,
MD, USA) at 35‡C with shaking at 220 rpm served as the in-
oculum source. The MIC is de¢ned as the lowest antibiotic con-
centration that resulted in no visible growth after incubation at
35‡C for 22 h.
5.2. Immobilization of glycopeptides
DCB-PV (5.4 Wmol) or PV (5.4 Wmol) was coupled to NHS-
activated Sepharose 4B (10 Wmol capacity) in a 1 ml Hi-Trap
column using a modi¢cation of the manufacturer’s protocols.
Due to the limited aqueous solubility of the glycopeptides, the
couplings were performed in N,N-dimethyl formamide bu¡ered
with three equivalents of triethylamine (4‡C, 12 h). The amount
of free glycopeptide remaining after each coupling reaction was
quanti¢ed by C18-reversed phase high pressure liquid chromatog-
raphy to calculate coupling e⁄ciencies for DCB-PV (75%) and
PV (82%). Residual NHS groups on the solid support were de-
activated with ethanolamine as recommended by the manufac-
turer. The 3,4-dichlorobenzyloxybenzyl putrescine derivative
DCBH was coupled to NHS-activated Sepharose using the
same protocols.
5.3. Preparation of solubilized E. coli membranes
E. coli strain MB4113A was grown to early stationary phase
(A600 = 1.5). Cells from a 4 l culture were harvested by centrifug-
ing at 8000Ug for 10 min, and washed once with 200 ml of 20
mM sodium phosphate bu¡er, pH 7.0. The cell pellet was resus-
pended in 60 ml of the same bu¡er and lysed by passage through
a French pressure cell (twice). Membranes were obtained by dif-
ferential centrifugation of the lysate (8000Ug for 10 min,
100 000Ug for 90 min). The pellet was resuspended in the same
bu¡er (V8 mg/ml total protein concentration as measured in a
Bradford assay with bovine serum albumin as standard), and
stored at 380‡C until further use. Membranes were solubilized
by the addition of an equal volume of 20 mM sodium phosphate
pH 7.0 bu¡er containing 2% (w/v) Triton X-100, 2 M NaCl,
followed by gentle shaking at 4‡C for 2 h.
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5.4. A⁄nity chromatography
The a⁄nity chromatography experiments were performed at
4‡C. Solubilized E. coli membranes (3^8 mg total protein) were
loaded on the glycopeptide/substituent a⁄nity columns (1 ml bed
volume, 7^12 Wmol binding capacity) at a £ow rate of 1 ml/h. The
columns were washed with 20 mM sodium phosphate, pH 7.0,
400 mM NaCl, 0.05% (w/v) Triton X-100 (20 column volumes, 30
ml/h). The columns were subsequently incubated for 12 h with
1 ml of elution bu¡er (20 mM sodium phosphate pH 7.0, 1%
Triton X-100), containing the appropriate free ligand (100 WM).
The columns were developed with elution bu¡er alone (12^13
column volumes, 30 ml/h) and 1 ml fractions were collected in
each case. Aliquots (7^10 Wl) of select fractions were analyzed by
SDS^PAGE (10% polyacrylamide gel) and proteins were visual-
ized by silver staining.
5.5. In situ tryptic digest and mass spectrometry of
eluted proteins
The SDS^PAGE gels containing protein bands eluted from the
a⁄nity columns and stained with Gelcode Blue1 were washed
extensively in water. Bands of interest were excised using dispos-
able scalpels. Gel fragments from individual bands were placed in
0.65 Wl microfuge tubes. Gel fragments were destained by wash-
ing with 50:50 acetonitrile:water followed by acetonitrile, and
then 50:50 100 mM ammonium bicarbonate:acetonitrile. At
each wash step, the tubes were vortexed for 10 min and the
wash solution was discarded. Volumes of each wash step were
su⁄cient to cover the gel fragments. After the last wash step, the
gel fragments were dried completely under vacuum. Gel pieces
were reconstituted in reduction bu¡er (10 mM tris(2-carboxy-
ethylphosphine) hydrochloride in 100 mM ammonium bicarbon-
ate). After 30 min, alkylation bu¡er was added (55 mM iodoacet-
amide in 100 mM ammonium bicarbonate). After a further 30
min incubation, the solution was removed. The gel fragments
were washed with 50:50 100 mM ammonium bicarbonate:aceto-
nitrile and then dried completely under vacuum. Reduced and
alkylated gel fragments were reconstituted in digestion bu¡er
(6 ng Promega modi¢ed trypsin per Wl of 100 mM ammonium
bicarbonate). The fragments were incubated at 37‡C for 10 h.
Following digestion, the supernatant was removed and placed
in clean microfuge tubes. The gel fragments were extracted with
equal volumes of 20% formic acid and 80% acetonitrile (30 min
sonication). The extract was combined with the supernatant and
the volume was reduced to 10^20 Wl under vacuum. Approxi-
mately half of the sample was loaded onto a 100 nm C18 self-
packed capillary HPLC column that was equilibrated with 0.1 M
acetic acid. An Applied Biosystems 130A HPLC was used to
deliver a linear gradient of 0.1 M acetic acid (solvent A) and
acetonitrile (solvent B) to the column (0^80% B). The column
was directly in line with a home-built micro-electrospray unit
mounted on a ThermoQuest LCQ electrospray mass spectrome-
ter. The spectrometer was operated under data-dependent condi-
tions to allow automatic acquisition of MS/MS spectra for any
peptide ion signal above a set intensity threshold. Upon comple-
tion of the gradient, data acquisition was terminated. The raw
data ¢le was then submitted for direct database correlation using
a home-constructed web-based interface to SEQUEST as previ-
ously described [48].
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